Patent intelligence · US
US 11986517
Cancer vaccines targeting mesothelin and uses thereof
Cancer vaccines targeting mesothelin and uses thereof
Patent details — US 11986517
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 21, 2024
- Expiration
- May 16, 2044
- Applicant
- Inovio Pharmaceuticals, Inc.
- Claims
- 3
- CPC classes
- A61K, A61K2039/53, A61K2039/55527, A61K2039/55538
Quick answer
US 11986517 (Cancer vaccines targeting mesothelin and uses thereof) is held by Inovio Pharmaceuticals, Inc.. Status: granted. Granted May 21, 2024. Expires May 16, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Inovio Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 3
- CPC classes
- A61K, A61K2039/53, A61K2039/55527, A61K2039/55538, A61K39/001168, A61K39/39
More from Inovio Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12285473
Cancer vaccines targeting MUC16 and uses thereof
granted -
US 12280108
Vaccines having an antigen and interleukin-21 as an adjuvant
granted -
US 12251561
Minimally invasive dermal electroporation device
granted -
US 12240872
Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
granted -
US 12161706
Cancer vaccines targeting BORIS and uses thereof
granted -
US 12109258
Synthetic malaria immunogens, combinations thereof, and their use to prevent and treat malaria infections
granted -
US 12064473
Cancer vaccines targeting Survivin and uses thereof
granted -
US 12054537
Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies
granted
Frequently asked questions
What is US patent 11986517?
US 11986517 (Cancer vaccines targeting mesothelin and uses thereof) is held by Inovio Pharmaceuticals, Inc.. Status: granted. Granted May 21, 2024. Expires May 16, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11986517?
Inovio Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 75 pharmaceutical patents for this assignee.
When does US 11986517 expire?
Our index shows an expiration date of May 16, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.